Click Here for 5% Off Your First Aladdin Purchase!

Epcoritamab (anti-CD3&CD20) - Primary antibody, specific to CD3E & MS4A1, Human IgG1, Antibody of CD20 (membrane-spanning 4-domains; subfamily A; member 1);Antibody of CD3e

  • Azide Free
  • Carrier Free
  • ExactAb™
  • Low Endotoxin
  • Recombinant
  • Validated
  • ≥90%(SDS-PAGE&SEC)
  • Lot by Lot
Features and benefits
  • Short Overview:

    Purity≥90% (SDS-PAGE&SEC); Endotoxin Level≤1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

  • Species reactivity(Reacts with): Cynomolgus monkey,Human
  • Isotype: Human IgG1
    Application:
  • Animal Model
  • ELISA
  • Flow Cytometry
  • Functional Assay
Item Number
Ab175531
Grouped product items
SKUSizeAvailabilityPrice Qty
Ab175531-100μg
100μg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$179.90
Ab175531-1mg
1mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$899.90
Ab175531-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$2,249.90
Ab175531-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$3,599.90

Purity≥90% (SDS-PAGE&SEC); Endotoxin Level≤1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

Basic Description

Product NameEpcoritamab (anti-CD3&CD20) - Primary antibody, specific to CD3E & MS4A1, Human IgG1
SynonymsGEN-3013;GEN3013
Specifications & PurityExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥90%(SDS-PAGE&SEC), Lot by Lot
SpecificityCD3E & MS4A1
ConjugationUnconjugated
GradeAzide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated
Action TypeBINDING AGENT
Mechanism of actionAntibody of CD20 (membrane-spanning 4-domains; subfamily A; member 1);Antibody of CD3e
Product Description

Epcoritamab (anti-CD3 & CD20) is an bispecific IgG1 antibody redirecting T-cells toward CD3×CD20+ tumor cells. Epcoritamab (anti-CD3 & CD20) induces potent T-cell-mediated cytotoxicity towards B-cell NHL cell lines.
Purity
≥90% (SDS-PAGE&SEC)
Endotoxin Level
≤1.0EU/mg

Product Properties

IsotypeHuman IgG1
Light Chain Typelambda
SDS-PAGE146.28 kDa
Purification MethodProtein A purified
ConcentrationLot by Lot
Storage TempStore at -80°C,Avoid repeated freezing and thawing
Shipped InIce chest + Ice pads
Stability And StorageStore at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS2134641-34-0

Associated Targets

MS4A1 Tclin B-lymphocyte antigen CD20 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CD3E Tclin T-cell surface glycoprotein CD3 epsilon chain 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Related Documents

References

1. van der Horst HJ, de Jonge AV, Hiemstra IH, Gelderloos AT, Berry DRAI, Hijmering NJ, van Essen HF, de Jong D, Chamuleau MED, Zweegman S et al..  (2021)  Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment..  Blood Cancer J,  11  (2): (38).  [PMID:33602901]
2. Engelberts PJ, Hiemstra IH, de Jong B, Schuurhuis DH, Meesters J, Beltran Hernandez I, Oostindie SC, Neijssen J, van den Brink EN, Horbach GJ et al..  (2020)  DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing..  EBioMedicine,  52  (3): (102625).  [PMID:31981978]

Solution Calculators